SYNGENE - Syngene International Limited Share Price

Healthcare Services

₹647.85-12.50(-1.89%)

Market Closed as of Jun 17, 2025, 15:30 IST

What does Syngene International Limited do?

Healthcare Research, Analytics & Technology•Healthcare•Mid Cap

Syngene International is a prominent company in the Healthcare Research, Analytics & Technology sector, trading under the stock ticker SYNGENE. With a substantial market capitalization of Rs. 27,358.4 Crores, it operates as a contract research and manufacturing organization providing a wide range of services in drug discovery and development.

The company offers extensive discovery chemistry services, including synthetic and medicinal chemistry, biomolecular science, organic electronic materials, and more. In addition, it delivers discovery biology services, focusing on areas like recombinant DNA engineering, toxicology, and protein sciences.

Syngene also specializes in chemical, formulation, analytical, and clinical development services, along with commercial manufacturing and sterile fill-finish services. Its offerings extend to lead generation, preclinical development, clinical trial management, pharmacokinetic analysis, and data management services.

Serving clients across various sectors such as pharmaceuticals, biotechnology, consumer goods, and agrochemicals, Syngene has established collaborations with notable companies including Bristol-Myers Squibb, Baxter Inc., and Amgen Inc.

Incorporated in 1993, the company is headquartered in Bengaluru, India, and functions as a subsidiary of Biocon Limited. Over the past twelve months, Syngene reported a revenue of Rs. 3,610.3 Crores and a profit of Rs. 501.5 Crores, highlighting its strong financial performance.

Investors benefit from a dividend yield of 0.3%, with a distribution of Rs. 2.5 per share in the last year. However, it is worth noting that the company has diluted shareholder equity by 0.4% in the past three years. Notably, Syngene has achieved a remarkable 41% revenue growth over the same period, emphasizing its growth trajectory in the industry.

Industry Group:Healthcare Services

Employees:6,510

Website:www.syngeneintl.com

Valuation
Market Cap	26.29 kCr
Price/Earnings (Trailing)	52.98
Price/Sales (Trailing)	7.08
EV/EBITDA	22.73
Price/Free Cashflow	64.55
MarketCap/EBT	39.84

Fundamentals
Revenue (TTM)	3.71 kCr
Rev. Growth (Yr)	11.14%
Rev. Growth (Qtr)	7.79%
Earnings (TTM)	496.2 Cr
Earnings Growth (Yr)	-2.81%
Earnings Growth (Qtr)	39.82%

Profitability
Operating Margin	16.91%
EBT Margin	17.77%
Return on Equity	10.5%
Return on Assets	7.3%
Free Cashflow Yield	1.55%

Pros

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Balance Sheet: Strong Balance Sheet.

Profitability: Recent profitability of 13% is a good sign.

Size: Market Cap wise it is among the top 20% companies of india.

Smart Money: Smart money is taking extra interest in the stock as they increase their holdings.

Cons

Momentum: Stock has a weak negative price momentum.

Technicals: SharesGuru indicator is Bearish.

Insider Trading: Significant insider selling noticed recently.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Sector Comparison: SYNGENE vs Healthcare Services

Comprehensive comparison against sector averages

Comparative Metrics

SYNGENE metrics compared to Healthcare

Category	SYNGENE	Healthcare
PE	53.14	42.46
PS	7.10	7.04
Growth	3.8 %	-0.1 %

Performance Comparison

SYNGENE vs Healthcare (2021 - 2025)

Key Insights

1. SYNGENE is among the Top 10 Healthcare Services companies but not in Top 5.
2. The company holds a market share of 4.8% in Healthcare Services.
3. In last one year, the company has had an above average growth that other Healthcare Services companies.

Share Holdings

Understand Syngene International ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

As of 2025-03-31

Shareholder Name	Holding %
BIOCON LIMITED	52.46%
ICICI PRUDENTIAL INNOVATION FUND	5.13%
MIRAE ASSET EQUITY SAVINGS FUND	3.94%
GOVERNMENT OF SINGAPORE	2.94%
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA FLE	1.87%
UTI NIFTY MIDSMALLCAP 400 MOMENTUM QUALITY 100 IND	1.83%
DSP NIFTY HEALTHCARE ETF	1.12%
BIOCON LIMITED EMPLOYEE WELFARE TRUST (MURALI KRISHNAN K N and K NANDA KUMAR)	0.26%
KIRAN MAZUMDAR SHAW	0.01%
BIOCON RESEARCH LIMITED	0%
RAVI RASENDRA MAZUMDAR	0%
DEV MAZUMDAR	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Latest News and Updates from Syngene International

Updated May 5, 2025

Syngene International's stock (SYNGENE) has experienced a notable decline of 26.85% this year, reflecting investor concerns. The current trading price is Rs 626.60, which is a decrease of 1.03% from the previous close. While there are some positive recommendations from analysts, the decrease in Foreign Institutional Investor holdings and a drop in share value over the past week suggest a challenging market position. The company's net profit of 183.30 Crores in the last quarter highlights some operational strength, but it has not offset the overall negative sentiment.

The Bad News

Mint

Syngene's stock has declined by 26.85% this year, reflecting significant downward pressure.

Mint

The stock price dropped by 1.03% today, with a recent trading range showing volatility.

Mint

Foreign Institutional Investor holdings have decreased to 19.47%, indicating reduced confidence among larger investors.

The Good News

Mint

Syngene International reported a net profit of 183.30 Crores in the last quarter, indicating operational strength.

Mint

Mutual Fund holdings in Syngene have increased to 17.86%, suggesting some level of investor confidence.

Mint

Among analysts, 2 recommend a strong buy for Syngene, indicating that some experts see potential upside.

This information is AI-generated and may contain inaccuracies. Please verify from multiple sources.

Cash Flow for Syngene International

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023
Finance costs	11.1%	31	28	34
Change in inventories	-28%	86	119	-153.4
Depreciation	-0.5%	367	369	359
Impairment loss / reversal	-	0	0	0
Unrealised forex losses/gains	76.7%	0	-3.3	24
Dividend income	-	0	0	0
Adjustments for interest income	-	55	0	60
Share-based payments	1805.9%	30	-0.7	21
Net Cashflows from Operations	20.1%	1,215	1,012	972
Income taxes paid (refund)	4.1%	102	98	134
Net Cashflows From Operating Activities	22%	1,114	913	838
Cashflows used in obtaining control of subsidiaries	-100.1%	0	931	18
Purchase of property, plant and equipment	5.1%	369	351	521
Proceeds from sales of intangible assets	-104.8%	0	22	0
Purchase of intangible assets	-49.3%	8.6	16	12
Interest received	-38.8%	50	81	54
Other inflows (outflows) of cash	-110.1%	-48.7	495	-166
Net Cashflows From Investing Activities	-111%	-810.4	-383.5	-688.2
Proceeds from issuing shares	-	0.5	0	0
Repayments of borrowings	-90.6%	42	436	258
Payments of lease liabilities	-	32	0	7.6
Dividends paid	0%	50	50	40
Interest paid	-29.4%	13	18	34
Net Cashflows from Financing Activities	74.4%	-136.5	-536.3	-340.2
Effect of exchange rate on cash eq.	-900%	0	0.9	3.1
Net change in cash and cash eq.	2653.8%	167	-5.5	-186.9

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023
Finance costs	18.2%	53	45	34
Change in inventories	-36%	74	115	-153.4
Depreciation	1.6%	433	426	366
Impairment loss / reversal	-	0	0	0
Unrealised forex losses/gains	78.3%	0	-3.6	24
Dividend income	-	0	0	0
Adjustments for interest income	-6.8%	56	60	60
Share-based payments	7300%	37	0.5	24
Net Cashflows from Operations	9.9%	1,283	1,167	960
Income taxes paid (refund)	-8.1%	115	125	137
Net Cashflows From Operating Activities	12.1%	1,168	1,042	824
Cashflows used in obtaining control of subsidiaries	-100.2%	0	553	18
Purchase of property, plant and equipment	54.6%	760	492	507
Purchase of intangible assets	-51.1%	9.8	19	12
Proceeds from sales of long-term assets	-104.8%	0	22	0
Interest received	-39.5%	50	82	54
Other inflows (outflows) of cash	-105.6%	-24.9	465	-171
Net Cashflows From Investing Activities	-50.2%	-744.7	-495.6	-656.4
Proceeds from issuing shares	-	0.5	0	0
Proceeds from borrowings	-	17	0	0
Repayments of borrowings	-90.6%	42	436	258
Payments of lease liabilities	47.2%	54	37	9.8
Dividends paid	0%	50	50	40
Interest paid	-53.6%	14	29	34
Net Cashflows from Financing Activities	74.1%	-141.8	-551.4	-342.5
Effect of exchange rate on cash eq.	-800%	0.3	1.1	3.1
Net change in cash and cash eq.	5933.3%	281	-3.8	-172.3

Investor Care
Dividend Yield	0.30%
Dividend/Share (TTM)	2.5
Shares Dilution (1Y)	0.13%
Diluted EPS (TTM)	12.34

Financial Health
Current Ratio	1.64
Debt/Equity	0.03
Debt/Cashflow	9.76

Income Statement for Syngene International

Standalone figures (in Rs. Crores) / View Consolidated Data

QuarterlyAnnual

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	8.1%	948	877	821	726	865	792
Other Income	0%	18	18	16	18	15	29
Total Income	8.1%	967	895	838	744	880	821
Cost of Materials	-7%	213	229	216	210	162	228
Employee Expense	-1.9%	209	213	224	196	195	196
Finance costs	57.9%	10	6.7	7	7.4	8.5	6.3
Depreciation and Amortization	-2.2%	90	92	94	92	96	94
Other expenses	10.6%	209	189	167	164	177	171
Total Expenses	1.8%	738	725	713	677	670	692
Profit Before exceptional items and Tax	34.9%	229	170	124	67	210	128
Exceptional items before tax	-	0	0	0	32	0	-3.7
Total profit before tax	34.9%	229	170	124	99	210	125
Current tax	2.6%	41	40	21	17	42	19
Deferred tax	118.2%	13	6.5	6.7	7.7	-20.9	5.8
Total tax	15.2%	54	47	28	25	21	25
Total profit (loss) for period	41.8%	174	123	97	74	190	100
Other comp. income net of taxes	205.4%	60	-55	-39.5	27	41	21
Total Comprehensive Income	247.8%	234	68	57	101	231	120
Earnings Per Share, Basic	61.4%	4.34	3.07	2.41	1.84	4.73	2.49
Earnings Per Share, Diluted	61.7%	4.33	3.06	2.41	1.84	4.72	2.48

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	5.3%	3,373	3,203	3,194	2,601	2,179	2,012
Other Income	-20.7%	70	88	71	53	65	82
Total Income	4.7%	3,444	3,291	3,264	2,654	2,244	2,094
Cost of Materials	3.5%	868	839	902	771	552	519
Employee Expense	10.7%	842	761	812	698	642	572
Finance costs	3.4%	31	30	45	24	28	35
Depreciation and Amortization	-0.5%	367	369	359	310	274	219
Other expenses	9.3%	729	667	587	361	341	304
Total Expenses	4.8%	2,854	2,723	2,664	2,142	1,812	1,649
Profit Before exceptional items and Tax	3.9%	590	568	601	512	432	444
Exceptional items before tax	356.2%	32	-11.1	0	-30.7	35	71
Total profit before tax	11.7%	622	557	601	482	467	516
Current tax	20.2%	120	100	116	88	74	89
Deferred tax	430%	34	-9	12	0	-9.9	15
Total tax	70%	154	91	128	88	64	104
Total profit (loss) for period	0.4%	468	466	473	394	404	412
Other comp. income net of taxes	-106.4%	-8.1	143	-97.2	43	191	-191.6
Total Comprehensive Income	-24.6%	460	610	376	437	594	220
Earnings Per Share, Basic	0.2%	11.64	11.62	11.81	9.89	10.15	10.36
Earnings Per Share, Diluted	0.2%	11.63	11.61	11.72	9.77	10.08	10.33

Consolidated figures (in Rs. Crores) / View Standalone Data

QuarterlyAnnual

Description	(%) Q/Q	Mar-2025	Dec-2024	Sep-2024	Jun-2024	Mar-2024	Dec-2023
Revenue From Operations	7.8%	1,018	944	891	790	917	854
Other Income	5.9%	19	18	16	18	16	29
Total Income	7.8%	1,037	962	908	808	933	883
Cost of Materials	-5.8%	228	242	231	168	172	240
Employee Expense	1.2%	253	250	252	230	227	221
Finance costs	36.4%	16	12	13	12	13	11
Depreciation and Amortization	-2.8%	106	109	111	107	111	108
Other expenses	7.6%	186	173	158	156	170	164
Total Expenses	1.9%	796	781	770	738	724	741
Profit Before exceptional items and Tax	32.8%	240	181	137	69	209	142
Exceptional items before tax	-	0	0	0	32	0	-3.7
Total profit before tax	32.8%	240	181	137	101	209	138
Current tax	4.5%	47	45	27	19	42	24
Deferred tax	136.8%	10	4.8	3.8	6.4	-22	2.2
Total tax	14.3%	57	50	31	26	20	27
Total profit (loss) for period	40%	183	131	106	76	189	112
Other comp. income net of taxes	193.3%	55	-56.9	-40.3	27	41	21
Total Comprehensive Income	226%	239	74	66	103	230	132
Earnings Per Share, Basic	56.8%	4.56	3.27	2.64	1.89	4.7	2.78
Earnings Per Share, Diluted	57.5%	4.56	3.26	2.64	1.88	4.69	2.77

Description	(%) Q/Q	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021	Mar-2020
Revenue From Operations	4.4%	3,642	3,489	3,193	2,604	2,184	2,012
Other Income	-21.1%	72	91	71	53	65	82
Total Income	3.8%	3,714	3,579	3,264	2,657	2,249	2,094
Cost of Materials	5.8%	925	874	902	771	552	519
Employee Expense	10.7%	984	889	842	718	660	580
Finance costs	13%	53	47	45	24	28	35
Depreciation and Amortization	1.6%	433	426	366	310	274	219
Other expenses	2.9%	674	655	557	341	326	294
Total Expenses	4.7%	3,086	2,947	2,670	2,142	1,815	1,648
Profit Before exceptional items and Tax	-0.6%	628	632	594	515	434	446
Exceptional items before tax	356.2%	32	-11.1	0	-30.7	35	71
Total profit before tax	6.3%	660	621	594	484	469	517
Current tax	12.3%	138	123	117	89	74	90
Deferred tax	281.8%	25	-12.2	12	0	-10.2	15
Total tax	48.2%	164	111	129	89	64	105
Total profit (loss) for period	-2.8%	496	510	464	396	405	412
Other comp. income net of taxes	-111.1%	-14.7	143	-97.2	43	191	-191.6
Total Comprehensive Income	-26.2%	482	653	367	439	596	220
Earnings Per Share, Basic	-3.1%	12.35	12.71	11.59	9.94	10.18	10.38
Earnings Per Share, Diluted	-3%	12.34	12.69	11.51	9.82	10.11	10.35

Balance Sheet for Syngene International

Standalone figures (in Rs. Crores) / View Consolidated Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	30.9%	234	179	67	128	72	157
Current investments	20.9%	598	495	493	488	824	829
Total current financial assets	20.6%	1,812	1,503	1,543	1,852	1,927	1,635
Inventories	-9.7%	150	166	234	315	333	267
Total current assets	17.3%	2,034	1,734	1,852	2,233	2,355	2,002
Property, plant and equipment	-11.6%	1,994	2,256	2,066	2,175	2,140	2,262
Capital work-in-progress	8.2%	875	809	758	146	126	229
Investment property	-10.8%	34	38	41	45	48	52
Non-current investments	99.8%	870	436	435	448	116	131
Total non-current financial assets	72.6%	1,080	626	652	666	336	316
Total non-current assets	8.9%	4,373	4,016	3,982	3,279	2,964	3,376
Total assets	11.4%	6,407	5,750	5,834	5,512	5,848	5,378
Borrowings, non-current	-101%	0	101	100	141	489	549
Total non-current financial liabilities	-38.9%	180	294	262	218	562	815
Provisions, non-current	-9.3%	40	44	38	34	42	42
Total non-current liabilities	-22.1%	439	563	544	526	860	1,072
Borrowings, current	146.3%	102	42	42	378	86	221
Total current financial liabilities	18.6%	542	457	382	733	440	635
Provisions, current	-13.3%	66	76	68	69	48	68
Current tax liabilities	-94.1%	4	52	46	13	13	50
Total current liabilities	53%	1,329	869	1,099	1,152	1,157	1,039
Total liabilities	23.5%	1,768	1,432	1,642	1,677	2,229	2,111
Equity share capital	0%	402	402	402	402	401	401
Total equity	7.4%	4,639	4,318	4,192	3,835	3,619	3,267
Total equity and liabilities	11.4%	6,407	5,750	5,834	5,512	5,848	5,378

Consolidated figures (in Rs. Crores) / View Standalone Data

Description	(%) Q/Q	Mar-2025	Sep-2024	Mar-2024	Sep-2023	Mar-2023	Sep-2022
Cash and cash equivalents	66.4%	367	221	86	168	90	159
Current investments	21.3%	610	503	513	492	824	829
Total current financial assets	25.8%	2,002	1,592	1,608	1,962	1,987	1,636
Inventories	-8.3%	156	170	238	320	333	267
Total current assets	21.9%	2,287	1,877	1,959	2,375	2,425	2,002
Property, plant and equipment	-16.9%	2,323	2,794	2,378	2,682	2,383	2,262
Capital work-in-progress	39.5%	1,261	904	837	236	177	229
Investment property	-10.8%	34	38	41	44	48	52
Non-current investments	0%	36	36	35	48	94	130
Total non-current financial assets	8.7%	252	232	258	271	329	316
Total non-current assets	5.9%	4,509	4,259	4,193	3,471	3,406	3,379
Total assets	10.8%	6,796	6,136	6,152	5,846	5,831	5,381
Borrowings, non-current	-101%	0	100	100	141	489	549
Total non-current financial liabilities	-22.2%	411	528	465	420	725	815
Provisions, non-current	-8.7%	43	47	41	36	44	42
Total non-current liabilities	-15.9%	673	800	750	729	1,025	1,072
Borrowings, current	105.2%	120	59	42	378	86	221
Total current financial liabilities	14.8%	597	520	413	794	466	628
Provisions, current	-13.6%	71	82	73	74	51	68
Current tax liabilities	-86%	8.4	54	48	20	15	53
Total current liabilities	48.4%	1,396	941	1,144	1,226	1,188	1,035
Total liabilities	18.9%	2,069	1,740	1,894	1,955	2,213	2,107
Equity share capital	0%	402	402	402	402	401	401
Total equity	7.5%	4,727	4,396	4,258	3,891	3,618	3,274
Total equity and liabilities	10.8%	6,796	6,136	6,152	5,846	5,831	5,381

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
SUNPHARMA	Sun Pharmaceutical IndustriesPharmaceuticals	4.05 LCr	53.56 kCr	-4.71%	+9.04%	35.31	7.56	+10.28%	+28.38%
DIVISLAB	Divi's LabPharmaceuticals	1.77 LCr	9.42 kCr	+4.12%	+42.48%	85.63	18.78	+20.50%	+49.46%
BIOCON	BioconPharmaceuticals	42.67 kCr	16.01 kCr	+3.62%	+5.05%	35.77	2.66	+2.75%	-19.91%
LAURUSLABS	Laurus LabsPharmaceuticals	35.54 kCr	5.31 kCr	+9.28%	+51.53%	177.16	6.69	+6.35%	+4.19%
JUBLPHARMA	JUBILANT PHARMOVAPharmaceuticals	17.43 kCr	5.53 kCr	+18.44%	+48.10%	25.67	3.15	-17.26%	+1897.12%

SYNGENE - Syngene International Limited Share Price

What does Syngene International Limited do?

Valuation

Fundamentals

Profitability

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

The Bad News

The Good News

Investor Care

Financial Health

Updates from Syngene International